Cardiovascular

Latest News

Semaglutide injectors and stethoscope | Image credit: Nati – stock.adobe.com
Semaglutide Linked to Cardiovascular Gains, but Also Higher Health Spending

August 8th 2025

A real-world study found that semaglutide prescriptions were associated with improvements in weight, blood pressure, and cholesterol, but also a $80 monthly rise in health care spending outside of drug costs.

Lp(a) test tube | Image credit: luchschenF – stock.adobe.com
Community Health Centers Expand Lp(a) Screening to Reduce Cardiovascular Risk

August 7th 2025

Teenage boy getting blood pressure checked | Image Credit: Halfpoint - stock.adobe.com
Pediatric Hypertension Increasing Among Children, Adolescents Worldwide

July 28th 2025

Eliquis packaging | Image credit: Semi – stock.adobe.com
Direct-to-Patient Apixaban Program Aims to Expand Access, Lower Out-of-Pocket Costs

July 17th 2025

Blood pressure monitor on patient's arm | Image credit: CasanoWa Stutio – stock.adobe.com
Delayed Hypertension Diagnosis Tied to Higher Cardiovascular Risk, Lower Treatment Rates

July 14th 2025

Lipoprotein(a) and Cardiovascular Risk

Learn about more about lipoprotein(a), including how to improve patient outcomes through better screening and management.

AJMC Peer Exchange logo
Continuing Medical Education
View All
August 9th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
August 9th 2025

Evidence-Based Guidelines Point to Leap in Care for Hypertrophic Cardiomyopathy

1.0 Credit / Cardiology
August 9th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health
August 9th 2025

Driving Better Outcomes in Hypertrophic Cardiomyopathy: A Managed Care Imperative

1.5 Credits / Cardiology
August 9th 2025

The Evolving Landscape of Transthyretin Amyloidosis Cardiomyopathy: New Therapies and Treatment Strategies

1.5 Credits / Cardiology, Rare Diseases
August 9th 2025

Pulmonary Arterial Hypertension: Real-World Applications of New Therapies and Management Strategies

1.5 Credits / Pulmonology, Cardiology, Rare Diseases

More News

Any Physical Activity Lowers CVD Risk for Elderly, Study Finds
November 29th 2017

Any Physical Activity Lowers CVD Risk for Elderly, Study Finds

Jaime Rosenberg
Physical activity, even of a low-intensity, reduces the risk of cardiovascular disease in older adults, according to a study published in The European Journal of Preventive Cardiology. Although the authors found similar associations for individuals under age 55 and individuals aged 55-65, the results were not statistically significant.
Site Logo
November 27th 2017

Cardiovascular Screenings Increase After the ACA, Study in The American Journal of Managed Care® Finds

Physicians’ response to policy changes in the Affordable Care Act show that changing cost-sharing formulas can make a difference, according to results reported by Drs. Joseph Ladapo and Dave Chokshi.
Systolic Blood Pressure of 140 mm Hg or Higher Should Be Treated to Prevent Death and CVD
November 23rd 2017

Systolic Blood Pressure of 140 mm Hg or Higher Should Be Treated to Prevent Death and CVD

Jaime Rosenberg
A study published in JAMA Internal Medicine found that blood pressure (BP) lowering is associated with reduced risk of death and cardiovascular disease (CVD) if the baseline systolic blood pressure (SBP) is 140 mm Hg or higher. Treatment may be considered in patients with coronary heart disease and SBP under 140 mm Hg, but not for primary prevention.
Site Logo
November 20th 2017

Changes in Cardiovascular Care Provision After the Affordable Care Act

Joseph A. Ladapo, MD, PhD Dave A. Chokshi, MD, MSc
The authors evaluated whether the 2010 Affordable Care Act was associated with changes in physicians’ provision of preventive cardiovascular services.
Dr Justin Bachmann: Challenges of Implementing Behavioral Interventions in Cardiac Care
November 18th 2017

Dr Justin Bachmann: Challenges of Implementing Behavioral Interventions in Cardiac Care

The biggest challenge of implementing behavioral interventions to improve care for patients with cardiovascular disease is reimbursement models, said Justin Bachmann, MD, MPH, FACC, Cardiologist and Clinical Investigator, Instructor of Medicine and Health Policy, Vanderbilt University Medical Center.
Site Logo
November 15th 2017

Xarelto Plus Aspirin: Based on COMPASS, It Cuts Costs

Mary Caffrey
The analysis presented at the American Heart Association looks strictly at healthcare costs, but a broader cost-effectiveness study is planned that will consider drug costs as well as effect on patient quality of life.
Site Logo
November 15th 2017

Researchers Dig Deeper on SGLT2 Inhibitors and Find Plenty of News

Mary Caffrey
Researchers presenting at the American Heart Association look at specific populations within 2 large diabetes drug trials, CANVAS and EMPA-REG OUTCOME.
Dr John Rumsfeld: We're Just at the Beginning of the Digital Health Transformation
November 9th 2017

Dr John Rumsfeld: We're Just at the Beginning of the Digital Health Transformation

Digital health, artificial intelligence and machine learning, and precision medicine are the areas where there is the most excitement in innovations for cardiovascular care, said John Rumsfeld, MD, PhD, chief innovation officer at the American College of Cardiology.
Site Logo
November 7th 2017

Rheumatology Patients at Increased Risk for Cardiac Disease

Kelly Davio
During a session at the 2017 American College of Rheumatology Annual Meeting in San Diego, California, a cardiologist joined rheumatologists to give a detailed look at the relationship between rheumatic conditions and cardiovascular disease.
Christi Deaton: Challenges of Motivating Patients to Participate in CVD Prevention Strategies
November 4th 2017

Christi Deaton: Challenges of Motivating Patients to Participate in CVD Prevention Strategies

The biggest challenges in promoting cardiovascular prevention strategies is motivating people to change a lifetime of poor habits into healthier habits, explained Christi Deaton, PhD, RN, FAHA, FESC, of the University of Cambridge.
Dr John Rumsfeld on the Digital Transformation of Cardiovascular Medicine
October 24th 2017

Dr John Rumsfeld on the Digital Transformation of Cardiovascular Medicine

The digital transformation of the cardiology field in the coming years will have a huge impact on the delivery of healthcare, said John Rumsfeld, MD, PhD, chief innovation officer at the American College of Cardiology.
Site Logo
October 23rd 2017

Teens Are Sleeping Less, and Smartphones Are Blamed

Mary Caffrey
The authors find that sleep in teens fell after 2009, as smartphone use escalated. Lack of sleep has been linked to insulin resistance.
Site Logo
October 13th 2017

Countywide Physician Organization Learning Collaborative and Changes in Hospitalization Rates

Brent D. Fulton, PhD, MBA Susan L. Ivey, MD, MHSA Hector P. Rodriguez, PhD, MPH Stephen M. Shortell, PhD, MPH, MBA
The University of Best Practices physician organization learning collaborative in San Diego County was associated with lower hospitalization rates for heart attacks.
Site Logo
October 12th 2017

Higher Physical Activity Lowers Risk of Mortality and Cardiovascular Disease

Jaime Rosenberg
A study has found that both recreational and non-recreational activity reduces the risk of mortality and cardiovascular disease, regardless of the country's economic status.
Site Logo
October 11th 2017

Lower LDL Cholesterol Associated With Higher Mortality in American Indians

Laura Joszt, MA
Excessively low levels of low-density lipoprotein cholesterol and triglycerides is associated with a higher all-cause mortality among American Indians, according to a new study published online ahead of print in Journal of Diabetes and Its Complications.
Dr Simon Gibbs Discusses the Future of Pulmonary Hypertension Treatments
October 3rd 2017

Dr Simon Gibbs Discusses the Future of Pulmonary Hypertension Treatments

Current drugs for pulmonary hypertension treat 3 pathways, but currently there aren't any new drugs to treat different pathways, although there likely will be some in the future, said Simon Gibbs, MD, Reader in Pulmonary Hypertension at the National Heart and Lung Institute, Imperial College London.
Dr Steven Nissen Argues for Aggressively Lowering LDL Cholesterol
October 1st 2017

Dr Steven Nissen Argues for Aggressively Lowering LDL Cholesterol

There is an ongoing debate about how aggressively to lower low-density lipoprotein (LDL) cholesterol, but Steve Nissen, MD, of Cleveland Clinic, argues that studies have shown an aggressive approach to lowering LDL always shows benefits.
Site Logo
September 18th 2017

Early Trauma, Depression, and the Need for Social Connection

Mary Caffrey
Experts said that the frequency and quality of social relationships have a greater effect on mortality than obesity or drinking alcohol, and this commands attention from health systems.
Site Logo
September 15th 2017

5 Facts About Air Pollution's Impact on Health

Laura Joszt, MA
In the wake of Hurricane Harvey, Houston is expected to face a host of health challenges, including air pollution. Here are 5 facts about how air pollution affects people’s health.
Site Logo
September 13th 2017

Statin Drug Use in COPD Patients Linked to Mortality Reductions

Alison Rodriguez
The use of statin drugs in patients with chronic obstructive pulmonary disease is associated with benefits including decreased lung-related and all-cause mortality, according to a research.
Dr Jeanette Stingone on Lasting Cardiovascular Effects of Prenatal Exposure to Air Pollution
September 7th 2017

Dr Jeanette Stingone on Lasting Cardiovascular Effects of Prenatal Exposure to Air Pollution

Researchers have known for years: what happens to mom in pregnancy affects the baby. That holds true with prenatal exposure to air pollution, which has lingering cardiovascular effects, such as birth defects and a higher risk of obesity, explained Jeanette Stingone, PhD, of Mount Sinai Health System.
This Week in Managed Care: September 1, 2017
September 1st 2017

This Week in Managed Care: September 1, 2017

This week, the top managed care stories included responses to the disaster in Houston after Hurricane Harvey; the approval of the first gene therapy in the United States; and a new cardiovascular indication for a popular drug to treat type 2 diabetes.
Site Logo
August 31st 2017

Liraglutide Improves Renal Outcomes in Type 2 Diabetes Patients With CV Risk

Mary Caffrey
The study finds that the GLP-1 receptor agonist can slow progression of kidney disease, one of the most costly and debilitating complications of type 2 diabetes.
Site Logo
August 30th 2017

Study in Lancet Challenges Diet Wisdom About Fat, Vegetables

Mary Caffrey
The findings will likely add to the controversy over the US dietary guidelines. Lobbyists for grain interests have long been accused of having undue influence in food policy, especially over the now-discarded "food pyramid."
Dr John Eikelboom: COMPASS' Rivaroxaban Plus Aspirin Will Become Standard for CAD, PAD
August 29th 2017

Dr John Eikelboom: COMPASS' Rivaroxaban Plus Aspirin Will Become Standard for CAD, PAD

The rivaroxaban plus aspirin combination therapy to treat patients with stable coronary or peripheral artery disease showed such benefits in the COMPASS trial that it should become the standard of care, said John Eikelboom, MBBS, MSc, FRCPC, associate professor at McMaster University.
Dr Deepak Bhatt Highlights COMPASS Trial Results
August 28th 2017

Dr Deepak Bhatt Highlights COMPASS Trial Results

The results of the COMPASS trial testing rivaroxaban plus aspirin in patients with coronary artery disease or peripheral artery disease showed such significant benefits for reducing ischemic events that it was stopped early, explained Deepak Bhatt, MD, MPH, of Brigham and Women's Hospital and Harvard Medical School.
Site Logo
August 27th 2017

An Eye on Cardiovascular Prevention: Begin in Childhood, Identify All Risk Factors

Laura Joszt, MA
For each level of cardiovascular risk, lifestyle factors remain a significant contributor that can be modified to reduce risk. However, some risk will remain nonmodifiable and require therapy, according to panelists during a session on cardiovascular prevention at the European Society of Cardiology Congress 2017, held August 26-30 in Barcelona, Spain.
Site Logo
August 27th 2017

COMPASS: Rivaroxaban Plus Aspirin Protects Against Heart Attack, Stroke

Laura Joszt, MA
Rivaroxaban plus aspirin has significant benefits for patients with peripheral artery disease (PAD) and stable coronary artery disease, according to the results of the COMPASS (Cardiovascular OutcoMes for People using Anticoagulation StrategieS) trial, presented at the European Society of Cardiology Congress 2017, held August 26-30 in Barcelona, Spain.
Dr Steven Nissen Outlines New Treatments in Cardiovascular Medicine
August 26th 2017

Dr Steven Nissen Outlines New Treatments in Cardiovascular Medicine

Trial results that will be presented at the European Society of Cardiology Congress 2017 in Barcelona, Spain, will open up a new window into treatment for patients at risk of major cardiovascular events, explained Steven E. Nissen, MD, of Cleveland Clinic, at the start of the conference.
Site Logo
August 25th 2017

Liraglutide Gains New Indication for Reducing CV Event Risk

Christina Mattina
Novo Nordisk announced that its diabetes drug liraglutide (Victoza) has been approved by the FDA for a new indication: it can reduce the risk of major cardiovascular (CV) events in patients with type 2 diabetes (T2D) and existing CV disease.
<1
...
111213141516171819
...
25>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo